Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 20:27:100544.
doi: 10.1016/j.eclinm.2020.100544. eCollection 2020 Oct.

Disease burden of inflammatory bowel disease in China from 1990 to 2017: Findings from the global burden of diseases 2017

Yan Qiu  1 , Wen Ren  1 , Ying Liu  1 , Wei-Er Chen  2 , Xiao-Hua Pan  2 , Jing-Jing Ren  1
Affiliations

Disease burden of inflammatory bowel disease in China from 1990 to 2017: Findings from the global burden of diseases 2017

Yan Qiu et al. EClinicalMedicine. .

Abstract

Background: A comprehensive evaluation of the burden of inflammation bowel disease (IBD) is important for identifying potential strategies to control the disease. We present results from the Global Burden of Diseases (GBD) 2017 of IBD at the national level, the trends in disease burden and its epidemiological features in China.

Methods: Using the methods and results from GBD 2017, we describe the IBD burden based on the prevalence, incidence, mortality, years of lost (YLLs), the years of life lived with disability (YLDs) and disability-adjusted life years (DALYs) in China estimated using DisMod-MR 2·1. We additionally evaluated the rate of DALYs at national locations in 2017.

Findings: From 1990 to 2017, the cases, deaths, YLLs, YLDs and DALYs for IBD in China were from 1,047,991 to 2,665,081, from 5701 to 5198, from 188,814 to 107,373, from 157,581 to 394,887, from 346,396 to 502,260, respectively. Increasing trends were observed in prevalence (APC: 2·9%), incidence (APC: 1·1%), DALYs (APC: 0·8%) and YLDs (APC:2·9%). There were decreasing trends in mortality (APC: -1·0%) and YLLs (APC: -2·7%). As to the age-standardized rates of DALYs, it observed a decreasing trend (APC: -0·78%). Similar trends were observed in men and women. The age-standardized APCs in incidence, mortality and rate of YLLs among women were higher than those among men. The age-standardized rate of DALYs was 27·51 per 100,000 in 2017.

Interpretation: Between 1990 and 2017, China experienced a decrease in the age-standardized DALYs, mortality rates and YLLs due to IBD, despite an increase in the age-standardized rate of prevalence, incidence and YLDs. China is still one of the low endemic areas.

Funding: This work had no supporting funding.

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests.

Figures

Fig. 1
Fig. 1
Observed and age-standardized rates (ARs) of IBD from 1990 to 2017 in China. (A) Observed and ARs of the prevalence; (B) Observed and ARs of the incidence; (C) Observed and ARs of the mortality; (D) Observed and ARs of the DALYs. DALYs=disability-adjusted life years.
Fig. 2
Fig. 2
Disease burden of IBD among different sex groups from 1990 to 2017 in China. (A) The differences in prevalence between males and females; (B) the differences in incidence between males and females; (C) the differences of mortality between males and females; (D) the differences in DALYs between males and females. DALYs=disability-adjusted life years.
Fig. 3
Fig. 3
Disease burden of IBD among different age groups from 1990 to 2017 in China. (A) The changes in prevalence of IBD among different age groups; (B) the changes in incidence of IBD among different age groups; (C) the changes in mortality of IBD among different age groups; (D) the changes in rates of DALYs for IBD among different age groups. DALYs=disability-adjusted life years.
Fig. 4
Fig. 4
Age-standardized rate of DALYs per 100,000 for IBD by location for both sexes, 2017.
See this image and copyright information in PMC

References

    1. Kaplan G.G. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12(12):720–727. - PubMed
    1. de Groof E.J., Rossen N.G., van Rhijn B.D., Karregat E.P., Boonstra K., Hageman I. Burden of disease and increasing prevalence of inflammatory bowel disease in a population-based cohort in the Netherlands. Eur J Gastroenterol Hepatol. 2016;28(9):1065–1072. - PubMed
    1. Chen M.H., Mao R. Diagnosis and treatment of Chinese inflammatory bowel disease for 100 years. Chin J Dig. 2015;35(1):6–9.
    1. Ng S.C., Shi H.Y., Hamidi N., Underwood F.E., Tang W., Benchimol E.I. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769–2778. - PubMed
    1. Rocchi A., Benchimol E.I., Bernstein C.N., Bitton A., Feagan B., Panaccione R. Inflammatory bowel disease: a Canadian burden of illness review. Can J Gastroenterol. 2012;26(11):811–817. - PMC - PubMed